Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2

Active, not recruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

November 14, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

May 31, 2025

Conditions
AnosmiaAsymptomatic COVID-19COVID-19 Respiratory InfectionInfluenzaHealthyPASC Post Acute Sequelae of COVID 19
Interventions
DEVICE

AROMHA Longitudinal Smell Test

The AROMHA Longitudinal Smell Test is a self-administered, at-home smell test intended for use as a screening test by asymptomatic individuals to help prevent exposure to and spread of SARS-CoV-2, the virus that causes COVID-19, through a serial testing approach. The device consists of six versions of a smell card, each containing three unique odors.

Trial Locations (1)

02129

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Institute on Deafness and Other Communication Disorders (NIDCD)

NIH

lead

Massachusetts General Hospital

OTHER